Related Experiment Videos

Study of growth hormone secretion and action in growth-retarded children with juvenile chronic arthritis (JCA)

A Tsatsoulis1, A Siamopoulou, C Petsoukis

  • 1Endocrine Unit, Department of Medicine, Department of Paediatrics, University of Ioannina, Ioannina, Greece. atsatsou@cc.uoi.gr

Insights

Growth hormone (GH) secretion is normal in children with juvenile chronic arthritis (JCA), but their bodies show reduced response to GH action. This suggests GH insensitivity contributes to growth retardation in JCA patients.

Area of Science:

  • Pediatric Endocrinology
  • Rheumatology
  • Growth Hormone Physiology

Background:

  • Growth retardation is a concern in children with juvenile chronic arthritis (JCA).
  • The underlying mechanisms, particularly concerning growth hormone (GH) action, require elucidation.

Purpose of the Study:

  • To investigate stimulated and spontaneous GH secretion in growth-retarded children with active systemic JCA.
  • To assess the response to GH action by evaluating Insulin-like Growth Factor-I (IGF-I) and IGF Binding Protein-3 (IGFBP-3) generation.

Main Methods:

  • Assessed GH responses to insulin-induced hypoglycemia and clonidine stimulation in six JCA patients.
  • Measured nocturnal pulsatile GH secretion via frequent blood sampling (20.00-08.00 h).
  • Conducted an IGF-I generation test using biosynthetic human GH (hGH) in JCA patients and controls.

Main Results:

  • JCA patients exhibited normal GH responses to stimulation tests and normal nocturnal GH pulse amplitude.
  • IGF-I and IGFBP-3 levels were significantly lower in JCA patients compared to controls.
  • JCA patients showed a blunted increase in IGF-I and IGFBP-3 following exogenous hGH administration compared to controls.

Conclusions:

  • Stimulated and spontaneous GH secretion are normal in children with active systemic JCA.
  • The impaired IGF-I and IGFBP-3 response to both endogenous and exogenous GH indicates GH insensitivity.
  • GH insensitivity is a likely contributing factor to growth retardation in children with active systemic JCA.

Related Concept Videos